Gene therapy restores vision in a canine model of childhood blindness
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The relationship between the neurosensory photoreceptors and the adjacent retinal pigment epithelium (RPE) controls not only normal retinal function, but also the pathogenesis of hereditary retinal degenerations. The molecular bases for both primary photoreceptor and RPE diseases that cause blindness have been identified. Gene therapy has been used successfully to slow degeneration in rodent models of primary photoreceptor diseases, but efficacy of gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported. Here we study one of the most clinically severe retinal degenerations, Leber congenital amaurosis (LCA). LCA causes near total blindness in infancy and can result from mutations in RPE65 (LCA, type II; MIM 180069 and 204100). A naturally occurring animal model, the RPE65-/- dog, suffers from early and severe visual impairment similar to that seen in human LCA. We used a recombinant adeno-associated virus (AAV) carrying wild-type RPE65 (AAV-RPE65) to test the efficacy of gene therapy in this model. Our results indicate that visual function was restored in this large animal model of childhood blindness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [64]
Citations
Cites
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Identification of the gene responsible for Best macular dystrophy
Petrukhin, K., Koisti, M. J., Bakall, B., Li, W., Xie, G., Marknell, T., Sandgren, O., Forsman, K., Holmgren, G., Andreasson, S., et al. (1998) · Nature Genetics · doi:10.1038/915 · Cited by 689
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Self-citationBiochemistry of visual pigment regeneration: the Friedenwald lecture.
Saari, J. C. (2000) · PubMed · Cited by 270
Simon, A., Hellman, U., Wernstedt, C., & Eriksson, U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1107 · Cited by 254
Van Hooser, J. P., Aleman, T. S., He, Y.-G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., & Palczewski, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150236297 · Cited by 252
Self-citationAguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Self-citationBennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242
Self-citation
Cited by
Items 901–1,000 of 1,000
Molecular Therapy for Choroideremia: Pre-clinical and Clinical Progress to Date
Kalatzis, V., Roux, A., & Meunier, I. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00558-y · Cited by 4
“Pre-clinical studies in an RPE65deficient canine model showed stable functional restoration following sub-retinal administration of an AAV2/2 vector expressing RPE65 under control of the CAG promoter [86, 87].”
BackgroundPark, S. A., Rhodes, J., Iwabe, S., Ying, G., Pan, W., Huang, J., & Komáromy, A. M. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109106 · Cited by 5
Dong, S., Zhen, F., Zou, T., Zhou, Y., Wu, J., Wang, T., & Zhang, H. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673240896231027053716 · Cited by 3
Intravitreal AAV2 gene delivery to feline retinal ganglion cells
Oikawa, K., Eaton, J. S., Kiland, J. A., Torné, O., Mathu, V., Nickells, R. W., & McLellan, G. J. (2024) · Vision Research · doi:10.1016/j.visres.2024.108519 · Cited by 3
“Pre-clinical studies in dogs bearing an RPE65 gene mutation supported human clinical trials that resulted in the first FDA approved ocular gene therapy (Acland et al., 2001; Beltran et al., 2012; Bennicelli et al., 2008; Petersen-Jones et al., 2012).”
Wei, S. C., Cantor, A. J., Walleshauser, J., Mepani, R. J., Melton, K., Bans, A., Khekare, P., Gupta, S., Wang, J., Soares, C., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317387 · Cited by 3
Clinical Applications of Gene Therapy
Giacca, M. (2010) · Springer eBooks · doi:10.1007/978-88-470-1643-9_4 · Cited by 3
Chapter 14 Genetically determined disorders of retinal function
Holder, G. E., & Robson, A. G. (2005) · Handbook of clinical neurophysiology · doi:10.1016/s1567-4231(09)70211-4 · Cited by 4
Brain structure, function, and genetics revealed by studies of the eye and face
Sisodiya, S. M. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283052d0c · Cited by 4
Plasma-mediated transfection of RPE
Palanker, D., Chalberg, T. W., Vankov, A., Huie, P., Molnar, F. E., Butterwick, A., Calos, M. P., Marmor, M. F., & Blumenkranz, M. S. (2006) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.649624 · Cited by 3
“Indeed, a number of studies have used viral vectors for gene delivery to photoreceptor cells [2-4] and RPE cells [5-7].”
BackgroundFortschritte in der somatischen Gentherapie von Netzhautdegenerationen am Tiermodell
Schlichtenbrede, F. C., Sarra, G., Ali, R. R., Wiedemann, P., & Reichel, M. B. (2002) · Der Ophthalmologe · doi:10.1007/s00347-002-0633-x · Cited by 3
Implants for artificial vision
Walter, P. (2009) · Expert Review of Ophthalmology · doi:10.1586/eop.09.42 · Cited by 3
Translational benefits of gene therapy to date
McMenamin, M. M. (2011) · Clinical Oncology and Cancer Research · doi:10.1007/s11805-011-0551-2 · Cited by 4
Evaluation of the canine RPE65 gene in affected dogs with generalized progressive retinal atrophy.
Dekomien, G., & Epplen, J. T. (2003) · PubMed · Cited by 5
Photoreceptor cell dysplasia in two Tippler pigeons
Moore, P. A., Munnell, J. F., Martin, C. L., Prasse, K. W., & Carmichael, K. P. (2004) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2004.04024.x · Cited by 3
Gene Therapy for Blinding Pediatric Eye Disorders
Dumitrescu, A. V., & Drack, A. V. (2015) · Advances in Pediatrics · doi:10.1016/j.yapd.2015.04.012 · Cited by 3
CORTICAL VISUAL NEUROPROSTHESES FOR THE BLIND
Fernández, E., Pelayo, F. J., Ahnelt, P. K., Ammermüller, J., & Normann, R. A. (2004) · Cited by 7
Fundamentals of Human Genetics
Wiggs, J. L. (2009) · Elsevier eBooks · doi:10.1016/b978-0-323-04332-8.00001-9 · Cited by 3
Dagnelie, G., Stronks, H. C., & Barry, M. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00069-0 · Cited by 3
Photorezeptortransplantation in die degenerative Netzhaut
Borsch, O., Santos‐Ferreira, T., & Ader, M. (2017) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0043-104421 · Cited by 5
“Bei einem vorliegenden und bekannten genetischen Defekt könnten diese Zellen durch eine Ex-vivo-Gentherapie, z.B. durch „Gene Editing“mittels CRISPR/Cas9, behandelt und danach zur Transplantation genutzt werden, was die Gefahr einer Immunantwort und damit einer Abstoßung des Transplantats deutlich verringert.”
BackgroundInfluentialGene therapy for Leber congenital amaurosis
Kumaran, N., Smith, A. J., Michaelides, M., Ali, R. R., & Bainbridge, J. W. (2018) · Expert Review of Ophthalmology · doi:10.1080/17469899.2018.1429916 · Cited by 4
“A lack of functional RPE65 results in deficiency of 11-cis retinal such that rod photoreceptor cells are unable to respond to light, causing profound night blindness from birth [1].”
BackgroundInfluentialStandard Operating Procedures for Common Laboratory Animal Ocular Procedures
Gilger, B. C., Bartoe, J. T., Eaton, J. S., & Boyd, R. F. (2018) · Springer eBooks · doi:10.1007/978-3-319-78364-2_2 · Cited by 4
Domestic Dogs, Gene Repair, and the “One Health” Approach
Travis, A. J. (2017) · Routledge eBooks · doi:10.4324/9781315168418-9 · Cited by 3
Gene therapy for inherited retinal diseases
Dhooge, P. P. A., Valkenburg, D., & Hoyng, C. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816222-4.00017-4 · Cited by 5
Friedlander, M. (2006) · Elsevier eBooks · doi:10.1016/b978-0-323-02598-0.50008-2 · Cited by 3
Stammzellbasierte Therapieansätze für retinale Erkrankungen
Bartsch, U., Linke, S., & Petrowitz, B. (2005) · Der Ophthalmologe · doi:10.1007/s00347-005-1188-4 · Cited by 3
Gene Therapy for Ocular Diseases
Kim, B. J., & Waheed, N. K. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780195326147.003.0052 · Cited by 3
Leber Congenital Amaurosis: Clinical, Genetic, and Therapeutic Perspectives
Koenekoop, R. K., Cremers, F. P. M., López, I., & den Hollander, A. I. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780195326147.003.0034 · Cited by 3
Gene mutations causing hereditary diseases in dogs
Switonski, M. (2004) · Animal Science Papers and Reports · Cited by 3
From Vivarium to Bedside: Lessons Learned from Animal Models
Budzynski, E., Lee, Y., Sakamoto, K., Naggert, J. K., & Nishina, P. M. (2006) · Ophthalmic Genetics · doi:10.1080/13816810600977192 · Cited by 3
Recent Results in Retinal Transplantation Give Hope for Restoring Vision
Aramant, R. B., Radtke, N. D., & Seiler, M. J. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-186-4_19 · Cited by 3
The Retinoid Cycle and Retinal Diseases
Palczewski, K., & Baehr, W. (2005) · Wiley eBooks · doi:10.1038/npg.els.0004067 · Cited by 3
The genetic loci of open-angle glaucoma
WIRTZ, M., & Samples, J. R. (2003) · Ophthalmology Clinics of North America · doi:10.1016/s0896-1549(03)00067-1 · Cited by 3
“Subretinal injection of this vector delayed photoreceptor cell death by 6 weeks in the mouse model and at least 4 months in the dog [91,92].”
BackgroundThe Human Genome Project and Eye Disease: Clinical Implications
Wiggs, J. L. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.11.1710 · Cited by 3
Natarajan, S. (2013) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.109372 · Cited by 3
“Gene therapies or cell transplantation therapies aim at the correction of defective genes or its effects in an organism,[30,31] at least in theory which make these approaches attractive.”
BackgroundBioethical Aspects of Human Geneticization
Leźnicki, M. (2020) · Studia Ecologiae et Bioethicae · doi:10.21697/seb.2020.18.3.02 · Cited by 3
Sortino, R., González-Díez, A., Navarro, S. M., Martínez‐Tambella, J., Paleo‐García, V., Calatayud, E., de Saralegui, P., Opar, E., Claparols, À., Quintanilla, J. A., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c18611 · Cited by 2
Nagiel, A., Russell, S. R., Lam, B. L., Comander, J., Alemán, T. S., Besirli, C. G., Sisk, R. A., Yang, P. G., Weng, C. Y., Chung, D. C., et al. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.07.007 · Cited by 4
Self-citationPesquisa translacional na oftalmologia: o caminho para a medicina personalizada
Siqueira, R. C. (2012) · Revista Brasileira de Oftalmologia · doi:10.1590/s0034-72802012000500015 · Cited by 3
“Por exemplo, uma forma molecular de amaurose congênita de Leber é causada pela falta da isomerase retinóide codificado por RPE65 e foi restaurado a visão em um modelo natural de cães desta doença utilizando um vetor viral adeno-associado para transferir uma versão normal de RPE65 para o epitélio pigmentado da retina(1…”
BackgroundResearch Opportunities in Vision: A Report of the U.S.-Indo Workshops on Collaborative Research
Balasubramanian, D., & Kaufman, P. L. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.06-0071 · Cited by 2
“Gene therapy restored functional vision in these dogs.(55) More recently, researchers have reported on successful gene-replacement therapy in mice lacking the RPGRIP gene.”
BackgroundFocus on vision: 3 decades of remarkable contributions to biology and medicine
Palczewski, K. (2011) · The FASEB Journal · doi:10.1096/fj.11-0202ufm · Cited by 2
Liu, X., & Zhang, Y. (2016) · Hereditary Genetics · doi:10.4172/2161-1041.1000163 · Cited by 2
“With this knowledge, progress of gene-replacement therapies for several inherited retinal diseases has been made through pre-clinical and clinical studies in recent years [5-10].”
BackgroundDisorders of the Posterior Segment
Larocca, R. D. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3949-5.50106-0 · Cited by 1
Mistry, A., Tanga, S., & Maji, B. (2023) · Springer eBooks · doi:10.1007/978-981-19-8520-1_11 · Cited by 3
Insights into adeno-associated virus-based ocular gene therapy: A bibliometric and visual analysis
Chen, X., Yu, Y., Nie, H., Qin, X., Bai, W., Ren, J., Yao, J., Li, J., & Jiang, Q. (2023) · Medicine · doi:10.1097/md.0000000000034043 · Cited by 2
“The reference citation burst in AAV-based ocular gene therapy started in the article published by Acland GM in 2001.[19] Maguire AM published the article with the most potent strength value in 2008.”
BackgroundBioengineering prospects in livestock production
Singh, A. P., Shrivastava, K., Hagos, T. H., & Pandey, H. O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-98385-3.00001-3 · Cited by 2
Zhang, P., & Xu, Z. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.04.005 · Cited by 6
Low Vision: What It's Like to Live with Vision Loss
Legge, G. E. (2026) · doi:10.1093/9780198946960.001.0001 · Cited by 2
Emerging Gene Therapy Treatments for Inherited Retinal Diseases
Bakall, B., Klein, K. A., & Hariprasad, S. M. (2018) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20180628-02 · Cited by 2
Rétinopathies pigmentaires : de la thérapie cellulaire à la signalisation intercellulaire
Sahel, J., Mohand‐Saïd, S., & Léveillard, T. (2005) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2004.12.007 · Cited by 2
Nonviral gene therapy for age-related macular degeneration
Thumann, G. (2011) · Expert Review of Ophthalmology · doi:10.1586/eop.10.83 · Cited by 2
Translational research in retinology
Siqueira, R. C., & Jorge (2011) · Clinical ophthalmology · doi:10.2147/opth.s25249 · Cited by 2
“For example, one molecular form of Leber’s congenital amaurosis is caused by the lack of retinoid isomerase encoded by the RPE65 gene and vision was restored in a naturally occurring canine model of this disease using an adeno-associated viral vector to transfer a normal version of RPE65 to the retinal pigment epithel…”
Progesterone as a potential neuroprotective treatment in the retina
Allen, R. S., & Stein, D. G. (2014) · Expert Review of Ophthalmology · doi:10.1586/17469899.2014.949673 · Cited by 2
“Even after treatment, secondary RGC degeneration and visual field loss can persist, and in normal tension glaucoma, RGC death is seen even in patients with normal intraocular pressure [13,22].”
BackgroundGenetic testing---swings and roundabouts: a view from the United Kingdom
Black, G. C. M. (2001) · British Journal of Ophthalmology · doi:10.1136/bjo.85.12.1402 · Cited by 2
“The situation is even more confusing for complex conditions. An example is glaucoma, a common, “treatable” group of conditions with a significant genetic basis. Here, the phenotypes remain as difficult to define as ever and as a result the susceptibility factors important for each subgroup remain undefined. While such…”
Background[Gene therapy for hereditary ophthalmological diseases: Advances and future perspectives].
Chacon-Camacho, O. F., Astorga-Carballo, A., & Zenteno, J. C. (2015) · PubMed · Cited by 7
La rétinopathie pigmentaire à la recherche d’une approche thérapeutique
Dufier, J. (2003) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)33859-2 · Cited by 3
Functional Nanoparticles for Molecular Imaging-Guided Gene Delivery and Therapy
Miao, T., Zhang, Y., Zeng, Y., Tian, R., & Liu, G. (2016) · Springer series in biomaterials science and engineering · doi:10.1007/978-981-10-0063-8_8 · Cited by 3
Self-citationRole of Mertk in RPE Phagocytosis and Retinal Disease
Vollrath, D., & Feng, W. (2004) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789812561756_0013 · Cited by 2
Gene Therapy for Retinal Disease
Bennett, J., & Maguire, A. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00034-5 · Cited by 2
Self-citationGenetic Pathways in Retinal Degenerations and Targets for Therapy
Leung, L.-S. B., Voleti, V. B., Lin, J. H., & Tsang, S. H. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780195326147.003.0021 · Cited by 2
Werner, P., Haskins, M. E., & Giger, U. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-370491-7.00002-7 · Cited by 2
Kerrison, J. B., & Newman, N. J. (2000) · Elsevier eBooks · doi:10.1016/b978-0-323-03354-1.50026-2 · Cited by 2
Genersatztherapie bei hereditären Netzhauterkrankungen
Mühlfriedel, R., Sothilingam, V., Tanimoto, N., & Seeliger, M. W. (2017) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0043-101817 · Cited by 3
“In den letzten Jahren konnte in einer Vielzahl von gentherapeutischen Ansätzen am Tiermodell die erfolgreiche Behandlung erblicher Netzhautdystrophien unter Verwendung von rAAV-Vektoren gezeigt werden [16,17].”
BackgroundAravand, P., Ramachandran, P. S., Shpylchak, I., Phelps, N. T., Nikonov, S. S., & Bennett, J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00215 · Cited by 2
“The animal then received bilateral gene transfer of 1.5E11 vg/eye subretinal AAV2.hRPE65v2 (Bennicelli et al., 2008), a recombinant AAV that delivers the wildtype hRPE65 cDNA driven by a constitutive (chicken β actin promoter with CMV enhancer) (Amado et al., 2010).”
BackgroundSelf-citationVisual prostheses and other assistive devices
Memon, M. A., & Rizzo, J. F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-7020-2983-7.00075-9 · Cited by 2
Stem Cells and Cellular Therapy
Friedlander, M., & Hinton, D. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00035-7 · Cited by 2
Bjerkås, E., Ekesten, B., Narfström, K. L., & Grahn, B. H. (2009) · Elsevier eBooks · doi:10.1016/b978-070202861-8.50010-5 · Cited by 8
Whitaker, J., Rogala, A. R., LeVine, D. N., & Fletcher, C. (2017) · CRC Press eBooks · doi:10.1201/9781315155807-4 · Cited by 2
RPE65 Mutation-associated Inherited Retinal Disease and Gene Therapies
Camp, D. A., Falabella, P., & Ciulla, T. A. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000381 · Cited by 2
Development of Viral Vectors with Optimal Transgene Expression for Ocular Gene Therapies
Hashimoto, T. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74904-4_12 · Cited by 3
Stem Cell and Gene Therapy for Inherited Retinal Diseases
DeSouza, P. J., Park, U. C., & Park, S. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-7337-5_3 · Cited by 2
Chapter 3 - Restoring Vision to the Blind: Gene Therapy for Vision Loss
Science, T. L. I. I. F. I. I. V. S. T. L. I. I. F. I. I. V. (2014) · Translational Vision Science & Technology · doi:10.1167/tvst.3.7.5 · Cited by 4
Large Animal Models of Retinitis Pigmentosa in Therapy Development and Preclinical Testing
Occelli, L. M., & Petersen‐Jones, S. M. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2651-1_22 · Cited by 2
Paterson, R. L., Roach, J. N. D., McLaren, T. L., Hewitt, A. W., Hoffmann, L., & Lamey, T. M. (2012) · PubMed Central · Cited by 2
Pediatric Visual Electrophysiology
Kriss, A., & Thompson, D. (2007) · Springer eBooks · doi:10.1007/0-387-27933-4_1 · Cited by 2
Retinoid Pathway Gene Mutations and the Pathophysiology of Related Visual Diseases
Tsybovsky, Y., & Palczewski, K. (2015) · Wiley eBooks · doi:10.1002/9781118628003.ch24 · Cited by 2
Terapia génica contra la retinosis pigmentaria
Vecino, E. (2008) · Archivos de la Sociedad Española de Oftalmología · doi:10.4321/s0365-66912008000400002 · Cited by 2
Averting abnormal inheritance: potential of gene therapy and preimplantation diagnosis
Thrasher, A. J., & Edward, R. G. (2004) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60503-2 · Cited by 2
“Introduction of therapeutic genes by relatively non-traumatic subretinal injection of adeno-associated virus vectors in several small and large animal models of inherited blindness has recently been shown to result in effective and durable restoration of photoreceptor function (Ali et al., 2000; Acland et al., 2001).”
BackgroundSugar Creates a Sticky Business: Round Up the Usual Suspects
Rosenbaum, J. T. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61099-1 · Cited by 2
Restoring Retinal Function in a Mouse Model of Hereditary Blindness
Moore, T. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020399 · Cited by 2
“The fi rst gene therapy trial in humans with early onset retinal dystrophies as a result of mutations in RPE65 is due to start within the next two years, and if this is successful, treatment of other disorders such as Lrat defi ciency will follow.”
InfluentialGenetics of the Retinal Dystrophies
Merepa, S. S., Broadgate, S., Sekaran, S., & Halford, S. (2018) · Wiley eBooks · doi:10.1002/9780470015902.a0028116 · Cited by 2
Le génome du chien : un modèle alternatif pour l’analyse fonctionnelle des gènes de mammifères
Galibert, F., & André, C. (2002) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)34147-0 · Cited by 2
Insight on the Rise and Raise of Drug Delivery with Special Emphasis on Five Classes of Therapeutics
Desavathu, M., Singh, P., Pal, A., Joshi, N., & Upadhyay, R. K. (2025) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2025053703 · Cited by 1
Ferreira, M. B., Marques, J. P., Raimundo, M., Quental, H., & Castelo-Branco, M. S. (2025) · Communications Medicine · doi:10.1038/s43856-025-00820-y · Cited by 2
“…biallelic disease-causing variants in RPE65 gene are usuallyassociatedwithaseverephenotype,rangingfromLCAtoSECORD/ ECORD 2 – 4,8 – 10 With the evolution of biotechnology, gene therapy (GT) is being increasingly used to enhance visual function in IRDs, both in animal models 5,11 and in humans 12 .”
Gene therapy advances using canine and feline animal models of inherited retinal degeneration
Petersen‐Jones, S. M., & Beckwith‐Cohen, B. (2025) · Eye · doi:10.1038/s41433-025-03825-y · Cited by 2
“The RPE65 mutant dog was important in providing the first proof-of-concept gene augmentation therapy for LCA2 [4].”
A Practical Approach to Retinal Dystrophies
Hondur, A., Tsui, I., Song, B. J., Lin, C., Tsang, S. H., Sharma, T., & Diaconita, V. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-72230-1_55 · Cited by 2
Amatha, S., Das, R., Gautam, M. K., & Mondal, S. (2025) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2025.03.009 · Cited by 2
Modalities of vision restoration in optic neuropathies and retinal disease
Rubin, B. R., Lavinsky, F., Cain, R., Kuriyan, A. E., Wollstein, G., Zambrano, R., & Schuman, J. S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101474 · Cited by 1
Neovascular Age-Related Macular Degeneration: Secretion Gene Therapy
Rakoczy, E. P., Lai, C., & Constable, I. J. (2014) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-662-45188-5_6 · Cited by 1
Assessing the Efficacy of Gene Therapy in Rpe65 -/- Mice Using Photoentrainment of Circadian Phythm
Stoddart, C. W., Yu, M. J. T., Martin-Iverson, M. T., Daniels, D. M., Lai, C. –., Barnett, N. L., Redmond, T. M., Narfström, K. L., & Rakoczy, P. E. (2007) · Springer eBooks · doi:10.1007/0-387-32442-9_34 · Cited by 1
Adeno‐associated virus mediated gene therapy for vascular retinopathies
Raisler, B. J., Deng, W., Berns, K. I., & Hauswirth, W. W. (2005) · Laboratory techniques in biochemistry and molecular biology · doi:10.1016/s0075-7535(05)31005-9 · Cited by 1
Self-citationMedical Space Oriented Color Psychology Perception Model
Li, C. F., & Shi, H. (2014) · Applied Mechanics and Materials · doi:10.4028/www.scientific.net/amm.587-589.461 · Cited by 1
“The most famous visible light therapy is Blue Ray Therapy [9] found by Cremer that can significantly decrease the Serum Bilirubin level in neonatal jaundice, which is gradually applied into the treatment of Serum Bilirubin [10].”
BackgroundRetinal Degenerations: Genetics, Mechanisms, and Therapies
MacDonald, I. M., Naash, M. I., & Ayyagari, R. (2011) · Journal of Ophthalmology · doi:10.1155/2011/764873 · Cited by 1
Electroretinographic Testing in Infants and Children
Birch, D. G., Birch, E. E., & Spencer, R. (2010) · Springer eBooks · doi:10.1007/978-3-642-12041-1_3 · Cited by 1
Postęp biologiczny w rolnictwie w erze genomiki i modyfikacji genetycznych
Switonski, M., & Malepszy, S. (2012) · Nauka · Cited by 1
Retinal Pigment Epithelium Derived from Embryonic Stem Cells
Klimanskaya, I. V. (2008) · Elsevier eBooks · doi:10.1016/b978-012369410-2.50051-6 · Cited by 1
Gene therapy for Stargardt and other ABCA4-related diseases: lessons from RPE65-LCA trials
Silva, N. F. A. (2010) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
Cell Therapy for Ophthalmic Diseases
Kauper, K., & Nystuen, A. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-57153-9_12 · Cited by 1
A Review of Personalised Molecular Medicine for the Treatment of Corneal Disorders
Courtney, D. G., Thakur, A., Ma, N., Moore, J. E., & Moore, T. (2015) · International Journal of Ophthalmology & Eye Science · doi:10.19070/2332-290x-si02002 · Cited by 1
“Initially tested in vivo in mouse [97, 98] and canine [99, 100] models of LCA, delivery of this therapeutic system by”
Recent milestone U.S. ophthalmic product approvals and clearances
Novack, G. D. (2018) · The Ocular Surface · doi:10.1016/j.jtos.2018.08.002 · Cited by 1
Stem Cells for Diseases of the Retina
Nagiel, A., & Schwartz, S. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809880-6.00022-9 · Cited by 1
Metadata
- Authors
- Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., Jacobson, S. G., Hauswirth, W. W., & Bennett, J.
- Affiliations
- Cornell University (US)
- University of Pennsylvania (US)
- University of Florida (US)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- Nature Genetics
- Published
- 2001-05
- Volume
- 28
- Issue
- 1
- Pages
- 92-95
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2141354154
- Cited by
- 1,202
- References
- 21
- Citations by year
- 2026: 29 · 2025: 26 · 2024: 19 · 2023: 24 · 2022: 26 · 2021: 38 · 2020: 35 · 2019: 36 · 2018: 39 · 2017: 41 · 2016: 33 · 2015: 40 · 2014: 56 · 2013: 48 · 2012: 64
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ey011142-05)
- National Eye Institute (EY10820, EY 06855, R01EY010820, EY 11142, R01EY013132, R01EY011123, EY-11123, EY 13132)
- National Institute of Neurological Disorders and Stroke (NS36202)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, Leber congenital amaurosis, RPE65, retinal pigment epithelium, photoreceptors, recombinant adeno-associated virus, childhood blindness, vision restoration, inherited retinal degeneration, large animal model
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Animals, Blindness, Carrier Proteins, Disease Models, Animal, Dog Diseases, Dogs, Eye Proteins, Proteins, Genetic Therapy, Optic Atrophies, Hereditary, cis-trans-Isomerases, Animals, Genetically Modified
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.